Hyderabad based Aurbindo Pharma has announced that the company has recieved final approval to market Alendronate Sodium trihydrate tablets (Generic equivalent of Merck's Fosamax) for 10mg, 35mg and 70mg. Alendronate Sodium trihydrate is indicated for the treatment of osteoporosis. Aurbindo is the first company to recieve approval after the expiry of combined 180 days exclusivity of Barr and Teva (which ended on 6th August). The Aurbindo's ANDA was reviewed with in 8 months by USFDA. Eralier, Barr and Teva launched their product in February, 2008, after the expiry of product patent.
Wednesday 6 August, 2008
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment